Associated Papers
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
41234595 (PubMed )
Supplement: tlcr-14-10-4235-supplementary.pdf
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_2.xlsx › ERBB2_Mutations
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR et al.
Chest, 2021
33878340 (PubMed )
Supplement: mmc1.pdf
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y et al.
Cancer Research and Treatment, 2021
32810930 (PubMed )
Supplement: crt-2020-559-suppl3.pdf
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
33087175 (PubMed )
Supplement: 40478_2020_1040_MOESM1_ESM.xlsx › Sheet1
Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z et al.
Carcinogenesis, 2020
Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Chen B et al.
Endocrine-related Cancer, 2020
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.
Subramanian J et al.
The Oncologist, 2019
Targeted sequencing of cancer-related genes in nasopharyngeal carcinoma identifies mutations in the TGF-β pathway.
Chung AK et al.
Cancer Medicine, 2019
31328403 (PubMed )
Supplement: CAM4-8-5116-s010.xlsx › ___1
Select a paper to view details